-
1
-
-
84918820589
-
PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
-
Marais AD, Kim JB, Wasserman SM, Lambert G. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2015;145:58-66. doi: 10. 1016/j. pharmthera. 2014. 07. 004
-
(2015)
Pharmacol Ther
, vol.145
, pp. 58-66
-
-
Marais, A.D.1
Kim, J.B.2
Wasserman, S.M.3
Lambert, G.4
-
2
-
-
84906716305
-
Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
-
Cuchel M, Bruckert E, Ginsberg HN, et al; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-2157. doi: 10. 1093/eurheartj/ehu274
-
(2014)
Eur Heart J
, vol.35
, pp. 2146-2157
-
-
European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia1
Cuchel, M.2
Bruckert, E.3
Ginsberg, H.N.4
-
3
-
-
81355160365
-
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy
-
Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais AD. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy. Circulation. 2011;124:2202-2207. doi: 10. 1161/ CIRCULATIONAHA. 111. 042523
-
(2011)
Circulation
, vol.124
, pp. 2202-2207
-
-
Raal, F.J.1
Pilcher, G.J.2
Panz, V.R.3
Van Deventer, H.E.4
Brice, B.C.5
Blom, D.J.6
Marais, A.D.7
-
4
-
-
84961288617
-
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab
-
Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA, Schwahn U, Gusarova V, Blom DJ, Sasiela W, Marais AD. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab. J Am Coll Cardiol. 2014;64:2299-2300. doi: 10. 1016/j. jacc. 2014. 07. 995
-
(2014)
J Am Coll Cardiol
, vol.64
, pp. 2299-2300
-
-
Lambert, G.1
Chatelais, M.2
Petrides, F.3
Passard, M.4
Thedrez, A.5
Rye, K.A.6
Schwahn, U.7
Gusarova, V.8
Blom, D.J.9
Sasiela, W.10
Marais, A.D.11
-
5
-
-
84887164358
-
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia
-
Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113-2120. doi: 10. 1161/CIRCULATIONAHA. 113. 004678
-
(2013)
Circulation
, vol.128
, pp. 2113-2120
-
-
Stein, E.A.1
Honarpour, N.2
Wasserman, S.M.3
Xu, F.4
Scott, R.5
Raal, F.J.6
-
6
-
-
84921459685
-
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial
-
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341-350. doi: 10. 1016/S0140-6736(14)61374-X
-
(2015)
Lancet
, vol.385
, pp. 341-350
-
-
Raal, F.J.1
Honarpour, N.2
Blom, D.J.3
Hovingh, G.K.4
Xu, F.5
Scott, R.6
Wasserman, S.M.7
Stein, E.A.8
-
7
-
-
0035906961
-
Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein
-
Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292:1394-1398. doi: 10. 1126/science. 1060458
-
(2001)
Science
, vol.292
, pp. 1394-1398
-
-
Garcia, C.K.1
Wilund, K.2
Arca, M.3
Zuliani, G.4
Fellin, R.5
Maioli, M.6
Calandra, S.7
Bertolini, S.8
Cossu, F.9
Grishin, N.10
Barnes, R.11
Cohen, J.C.12
Hobbs, H.H.13
-
8
-
-
33749487743
-
The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH
-
Maurer ME, Cooper JA. The adaptor protein Dab2 sorts LDL receptors into coated pits independently of AP-2 and ARH. J Cell Sci. 2006;119(pt 20):4235-4246. doi: 10. 1242/jcs. 03217
-
(2006)
J Cell Sci
, vol.119
, pp. 4235-4246
-
-
Maurer, M.E.1
Cooper, J.A.2
-
9
-
-
0036897341
-
Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1
-
Eden ER, Patel DD, Sun XM, Burden JJ, Themis M, Edwards M, Lee P, Neuwirth C, Naoumova RP, Soutar AK. Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1. J Clin Invest. 2002;110:1695-1702. doi: 10. 1172/JCI16445
-
(2002)
J Clin Invest
, vol.110
, pp. 1695-1702
-
-
Eden, E.R.1
Patel, D.D.2
Sun, X.M.3
Burden, J.J.4
Themis, M.5
Edwards, M.6
Lee, P.7
Neuwirth, C.8
Naoumova, R.P.9
Soutar, A.K.10
-
10
-
-
0037112908
-
Molecular mechanisms of autosomal recessive hypercholesterolemia
-
Wilund KR, Yi M, Campagna F, Arca M, Zuliani G, Fellin R, Ho YK, Garcia JV, Hobbs HH, Cohen JC. Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet. 2002;11:3019-3030
-
(2002)
Hum Mol Genet
, vol.11
, pp. 3019-3030
-
-
Wilund, K.R.1
Yi, M.2
Campagna, F.3
Arca, M.4
Zuliani, G.5
Fellin, R.6
Ho, Y.K.7
Garcia, J.V.8
Hobbs, H.H.9
Cohen, J.C.10
-
11
-
-
84860290100
-
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
-
Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, Kastelein JJ. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 2012;53:979-983. doi: 10. 1194/jlr. P023994
-
(2012)
J Lipid Res
, vol.53
, pp. 979-983
-
-
Huijgen, R.1
Fouchier, S.W.2
Denoun, M.3
Hutten, B.A.4
Vissers, M.N.5
Lambert, G.6
Kastelein, J.J.7
-
12
-
-
84902096056
-
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects
-
Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol. 2014;63:2365-2373. doi: 10. 1016/j. jacc. 2014. 02. 538
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 2365-2373
-
-
Lambert, G.1
Petrides, F.2
Chatelais, M.3
Blom, D.J.4
Choque, B.5
Tabet, F.6
Wong, G.7
Rye, K.A.8
Hooper, A.J.9
Burnett, J.R.10
Barter, P.J.11
Marais, A.D.12
-
13
-
-
60749122013
-
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells
-
Fasano T, Sun XM, Patel DD, Soutar AK. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis. 2009;203:166-171. doi: 10. 1016/j. atherosclerosis. 2008. 10. 027
-
(2009)
Atherosclerosis
, vol.203
, pp. 166-171
-
-
Fasano, T.1
Sun, X.M.2
Patel, D.D.3
Soutar, A.K.4
-
14
-
-
84952939391
-
Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort
-
Averna M, Cefalù AB, Stefanutti C, Di Giacomo S, Sirtori CR, Vigna G. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort. Nutr Metab Cardiovasc Dis. 2016;26:36-44. doi: 10. 1016/j. numecd. 2015. 11. 001
-
(2016)
Nutr Metab Cardiovasc Dis
, vol.26
, pp. 36-44
-
-
Averna, M.1
Cefalù, A.B.2
Stefanutti, C.3
Di Giacomo, S.4
Sirtori, C.R.5
Vigna, G.6
-
15
-
-
84871945617
-
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study
-
Cuchel M, Meagher EA, du Toit Theron H, et al; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-46. doi: 10. 1016/S0140-6736(12)61731-0
-
(2013)
Lancet
, vol.381
, pp. 40-46
-
-
Cuchel, M.1
Meagher, E.A.2
Du Toit, T.H.3
|